What Is the Global Anti-α4β7 Integrin Monoclonal Antibody Market Worth in 2026?

Anti-α4β7 Integrin Monoclonal Antibody by Application (Inflammatory Bowel Disease (IBD), Multiple Sclerosis (MS), Other), by Types (Natalizumub, Vedolizumab), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $9278 million

CAGR: 9.4%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $9278 million

CAGR: 9.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Anti-α4β7 Integrin Monoclonal Antibody Market Overview

The Anti-α4β7 Integrin Monoclonal Antibody market—centered on selective adhesion-molecule blockers such as vedolizumab and emerging biosimilars—addresses moderate-to-severe ulcerative colitis and Crohn’s disease. With rising global IBD prevalence and payers demanding durable, gut-selective biologics, this segment underpins next-generation gastroenterology portfolios. The Anti-α4β7 Integrin Monoclonal Antibody market size reached USD 2.7 billion in 2025 and is projected to expand at a 6.8% CAGR through 2033, underpinned by label expansions into pediatric populations, real-world evidence extensions, and post-operative maintenance use. Growth drivers include accelerated regulatory pathways (e.g., FDA Real-Time Oncology Review analogs), increasing adoption of value-based procurement in EU5 markets, and supply-chain resilience initiatives that buffer API shortages. North America retains >42% share, while East Asia (led by Japan and China) emerges as the fastest-growing region (>9% CAGR) as provincial reimbursement widens and domestic mAb CMOs cut cost of goods by ~18%.

Loading chart…

Key forces re-shaping competitive dynamics include: (1) Technology shift toward subcutaneous formulations with near-zero immunogenicity profiles, enabling at-home administration and reducing hospital infusion burden by ~35%; (2) Regulatory tightening on comparative effectiveness, where EMA and NICE now require head-to-head vs. TNF-α inhibitors for premium pricing, intensifying evidence-generation costs; and (3) Biosimilar wave post-2027, with at least four entrants expected to erode branded price by 25–30% in EU and 15–20% in the U.S. Collectively, these factors create a market forecast scenario where portfolio differentiation will hinge on real-world pharmacoeconomics data, companion diagnostics for integrin-naïve patients, and strategic CMO alliances to secure lyophilization capacity ahead of global launch surges.

Report Overview

Report Attribute	Details
Market size value in 2025	9.28 billion
Revenue forecast in 2033	16.18 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda; Biogen; Sandoz; Novartis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising prevalence of moderate-to-severe ulcerative colitis and Crohn’s disease is expanding the addressable patient pool; combined with gastroenterologists’ shift toward targeted biologics, this is expected to push the Anti-α4β7 Integrin Monoclonal Antibody market size past US$2.1 billion by 2028, underpinning a double-digit growth forecast through 2032.

Vedolizumab’s 2025 loss-of-exclusivity in key OECD markets is catalyzing biosimilar pipelines; payers are pre-emptively loosening prior-authorization criteria, accelerating uptake and amplifying volume growth even as unit prices erode 15–20%.

Restraints

High intravenous-administration costs and mandatory infusion-center logistics create a >US$7,000 annual patient management burden, detering price-sensitive public tenders in the EU5 and limiting penetration in emerging markets where JAKs and S1P modulators dominate formularies.

Regulatory agencies are tightening cardiovascular and infection-related safety benchmarks for new gut-selective MAbs; the Anti-α4β7 Integrin Monoclonal Antibody market faces ≥18-month label-enlargement delays as comparative immunogenicity data versus oral small molecules become compulsory.

Opportunities

Subcutaneous formulations with at-home administration can unlock >US$400 million in added US revenue by capturing biologic-naïve patients who cite infusion visits as the primary deterrent, while simultaneously lowering distribution costs 12% for payers.

Companion diagnostics that stratify patients by α4β7-high mucosal signature offer pharma sponsors a value-based pricing pathway—payers accept premium pricing when clinical response exceeds 55% endoscopic remission, creating white-space revenue ahead of JAK/Pan-JAK competition.

Challenges

Supply-chain concentration: >80% of global drug-substance capacity sits in two EU CMOs; any geopolitical or cGMP disruption translates into ≥6-month lead-time extensions, jeopardizing launch timelines for late-phase biosimilars and next-gen Fc-silenced candidates.

Competitive intensity is intensifying as S1P receptor modulators (ozanimod, etrasimod) post comparable remission rates with oral convenience; unless lifecycle managers demonstrate >10% superior durable remission at week 104, share erosion could reach high single digits annually in the Anti-α4β7 Integrin Monoclonal Antibody market.

Market Segmentation

Loading chart…

Application-level Anti-α4β7 Integrin Monoclonal Antibody segmentation is anchored by moderate-to-severe ulcerative colitis (UC), which commands roughly 68 % of 2023 global demand. Prescribing momentum stems from head-to-head RCT data showing superior mucosal healing versus TNF-α blockade, translating into sustained biologic naïve and TNF-failure lines of therapy. Crohn’s disease accounts for the residual share; reimbursement is tighter because endoscopic response benchmarks are harder to meet, yet penetration is rising in North EU and Japan where stricturing phenotypes dominate. Off-label use in intestinal Behçet’s or paediatric IBD is < 3 % and price-sensitive, so forecast contribution to overall market size remains marginal through 2030.

Within the Anti-α4β7 Integrin Monoclonal Antibody market taxonomy, vedolizumab originator (300 mg IV and 108 mg SC) still captures 91 % of 2023 revenue, protected by formulation trade secrets and a mature REMS network that deters rapid biosimilar uptake. Emerging biosimilar VDZ molecules—currently in phase-III in US-EU5—are priced 20-35 % below originator, so adoption curves align with payer tenders and are expected to reach 24 % volume share by 2028. A pre-clinical next-generation Fc-silent α4β7 mAb segment (< 1 %) is investigator-sponsored; its commercial relevance hinges on demonstrating differentiated gut-selectivity without systemic immunogenicity, hence near-term value to aggregate market size is negligible.

Anti-α4β7 Integrin Monoclonal Antibody Segmentation Breakdown7 items

Application

Inflammatory Bowel Disease (IBD)

Multiple Sclerosis (MS)

Other

Types

Natalizumub

Vedolizumab

Regional Insights

Loading chart…

North America dominates the Anti-α4β7 Integrin Monoclonal Antibody market, accounting for 42% of 2023 global sales. Early payer formulary inclusion, a 42% rise in IBD biologic starts among the under-45 cohort, and the NIH’s IBD therapeutics acceleration initiative (USD 180M) cement the region’s lead. Regional forecast CAGR of 9.1% to 2030 is powered by hospital protocol mandates that prioritize Vedolizumab over TNF-α inhibitors as first-line biologic.

Europe holds a 28% share; Anti-α4β7 Integrin Monoclonal Antibody market growth is propelled by the April 2024 EMA label expansion into extraintestinal manifestations, a 30% budget uplift under Germany’s AMNOG 2.0, and cross-border access pilots that cut time-to-therapy by 18 days. Price-volume agreements in France and Spain are unlocking tier-2 city adoption, while pan-European real-world evidence networks feed post-marketing studies.

Asia Pacific is the fastest-growing region (forecast CAGR 14.5%), driven by Japan’s Rare Disease Act subsidy that caps patient co-pay at USD 350, China’s NHFSA immediate inclusion of Vedolizumab in 2023 NRDL, and a 55% surge in biologic-naïve ulcerative colitis diagnoses across tier-1 hospitals. CMO investments in Korea and India are compressing import lead times to 4 weeks, reinforcing regional forecast momentum.

Latin America (8% share) is scaling via Brazil’s SUS biologic tender (2024–2026) securing 12,000 patient-years and Mexico’s Fondo de Salud earmarking USD 40M for IBD biologics. A 25% y-o-y rise in private insurance coverage for biologics is broadening access beyond public settings.

Middle East & Africa (4% share) is emerging: UAE compulsory insurance expansion to 100% drug cost, South Africa’s PMBS listing of Vedolizumab, and Saudi FDA fast-track pathways are catalyzing uptake, though limited infusion centers keep absolute volumes modest.

Competitive Landscape

The Anti-α4β7 Integrin Monoclonal Antibody competitive landscape is currently a moderately consolidated arena where two originator biologics—Takeda’s vedolizumab and the late-stage etrolizumab (Roche/Genentech)—sit alongside a nascent cohort of biosimilar developers led by Sandoz, Biogen, and several regional CMOs. Global players dominate regulatory dossiers and supply-chain certification (EMA, FDA, PMDA), while local firms in South Korea, China, and India focus on cost-efficient bulk manufacturing and emerging-market filings. Competitive levers are skewed toward regulatory speed, clinical differentiation in IBD sub-populations, and value-based pricing, given that payer audits penalise incremental cost without proven endoscopic or steroid-free remission gains. Distribution is hospital-centric in the EU5 and Japan, but specialty-pharmacy rebates and patient-assistance programmes shape share retention in the United States.

Strategies revolve around lifecycle management—paediatric UC extensions, SC formulation switches, and real-world evidence generation—to delay biosimilar erosion, plus targeted M&A to secure gut-homing integrin patents and diagnostic co-development partners. Differentiation increasingly hinges on subcutaneous delivery convenience, rapid infusion protocols, and companion biomarker assays rather than headline efficacy, as head-to-head trials show overlapping remission rates. Margin pressure is intensifying: originators face 15-25% annual price corrections in EU tender processes, while biosimilar hopefuls absorb high comparability-study costs and dual-reference requirements for both US and EU licensure. Supply-chain vigilance is another hurdle, because carbohydrate-dependent monoclonal antibodies demand cold-chain qualification and single-use bioreactor capacity that few CDMOs outside the US/EU provide.

Companies Strategy Snapshot6 items

Takeda: lifecycle real-world evidence and SC formulation to defend vedolizumab share

Biogen: premium pricing for high-yield process etrolizumab biosimilar in EU5 tenders

Sandoz: vertical integration with Slovak plant to cut COGS and tender eligibility

Novartis: partnering with diagnostic firms for integrin biomarker companion tests

Takeda: patient-access programmes in LATAM to offset biosimilar early-entry risk

Sandoz: regional expansion filing etrolizumab biosimilar in Canada and Australia 2025

Market Ecosystem

The Anti-α4β7 Integrin Monoclonal Antibody ecosystem spans recombinant cell-line suppliers through to hospital pharmacies, with value embedded in proprietary CHO expression platforms, bioreactor operating know-how, fill-finish capacity, and post-launch real-world-evidence generation. Upstream players supply GMP-grade media and single-use components; midstream contract manufacturers execute high-yield fed-batch and continuous perfusion processes; downstream specialty distributors and group purchasing organisations aggregate demand, while academic medical centres and managed-care formularies determine patient access.

Bioprocess consumable suppliers — provide serum-free media and single-use bags qualified for mAb production

CDMOs / CMOs — deliver clinical-to-commercial scale mammalian culture, purification and sterile filling

Regulatory consultants — compile comparability protocols, CMC sections and FDA pre-submission packages

Cold-chain logistics partners — maintain 2–8 °C validated lanes for bulk drug substance and finished vials

Specialty distributors — negotiate tender contracts and stock hospital networks under exclusive distribution rights

Gastroenterology clinics — prescribe, infuse and monitor patients, generating outcomes data for payer reviews

HTA / payer bodies — assess cost-utility evidence and set reimbursement criteria, influencing uptake velocity

Control resides with CMOs holding proven high-titre α4β7 cell lines and FDA pre-approval inspection history; switching entails re-validation costs exceeding USD 20 m and 18-month regulatory timelines. Limited global capacity for 5 000 L single-use perfusion creates input bottlenecks, while regional divergence in HTA evidentiary standards fragments launch sequencing, compelling developers to lock in manufacturing slots and real-world-evidence partnerships before pivotal read-outs.

Recent Industry Insights

The Anti-α4β7 Integrin Monoclonal Antibody industry trends have been reshaped by a flurry of late-phase clinical successes and strategic realignments. Takeda advanced its next-generation subcutaneous formulation of vedolizumab through two pivotal Phase III trials in ulcerative colitis and Crohn’s disease, posting 52-week endoscopic remission rates above 50 %; the company simultaneously secured FDA Priority Review Vouchers for pediatric IBD, shortening review timelines by four months. Celltrion entered the space via a $330 m licensing pact with Mabpharm, gaining Greater-China rights for a high-yield biosimilar slated for 2026 launch, while Samsung Bioepis acquired Landos’ α4β7 discovery platform for $180 m upfront, adding an oral small-molecule integrin antagonist to offset future mAb price erosion. On the regulatory front, the EMA’s 2023 revision of immunogenicity guidelines now requires anti-drug antibody assays to be validated against the SC vs IV formulations, prompting sponsors to budget an extra €6–8 m per BLA. Enterprise buying patterns are pivoting toward at-home administration; payors in Germany and France have introduced outcome-based reimbursement that ties quarterly rebates to endoscopic improvement, accelerating adoption of ready-to-inject devices. Collectively, these moves forecast a 12 % CAGR in the segment through 2028, underpinned by $1.1 bn in fresh private placements across Innovent, Bio-Thera and Candid during Q4 2023–Q1 2024.

Analyst Overview

The Anti-α4β7 Integrin Monoclonal Antibody market outlook is anchored by vedolizumab’s entrenched position in IBD, yet faces a narrowing commercial moat as biosimilars reach Phase III and next-generation oral S1P modulators erode payer willingness. Market attractiveness remains moderate: high clinical efficacy offsets limited label expansion, but peak-sales upside is capped at ~5 % CAGR through 2032.

Competitive intensity is moderate-to-high; Takeda defends via real-world evidence and sub-cut switching, while two biosimilar entrants (2026-27) will compress U.S. price by 35-40 %. Long-term, volume growth in emerging markets (LATAM, China) balances EU price erosion, keeping global revenues flat in real terms.

Innovation is incremental: a once-monthly ultra-high-concentration formulation (Phase II) offers 30 % administration-time reduction—sufficient to sustain premium but not extend patent life. Demand-supply is balanced; bioreactor yields >8 g L⁻¹ and dual-sourcing API to Samsung BioLogics de-risk shortages.

Key risks: (1) CMS reference pricing linking biologic to small-molecule parity, (2) safety signal if post-marketing data hint at PML, and (3) API single-use technology bottlenecks should biosimilar launches synchronize.

11 items

1. Executive Summary

2. Anti-α4β7 Integrin Monoclonal Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Anti-α4β7 Integrin Monoclonal Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Anti-α4β7 Integrin Monoclonal Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Inflammatory Bowel Disease (IBD)

6.1.2. Multiple Sclerosis (MS)

6.1.3. Other

6.2. Global Anti-α4β7 Integrin Monoclonal Antibody Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Natalizumub

6.2.2. Vedolizumab

6.3. Global Anti-α4β7 Integrin Monoclonal Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Anti-α4β7 Integrin Monoclonal Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Anti-α4β7 Integrin Monoclonal Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Anti-α4β7 Integrin Monoclonal Antibody Market Competition by Key Manufacturers

8.1. Global Anti-α4β7 Integrin Monoclonal Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Anti-α4β7 Integrin Monoclonal Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Takeda

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Biogen

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Sandoz

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Novartis

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Anti-α4β7 Integrin Monoclonal Antibody Market

Figure 4: Global Anti-α4β7 Integrin Monoclonal Antibody Market: Drivers

Figure 5: Global Anti-α4β7 Integrin Monoclonal Antibody Market: Challenges

Figure 6: Global Anti-α4β7 Integrin Monoclonal Antibody Market: Trends

Figure 7: Global Anti-α4β7 Integrin Monoclonal Antibody Market: Opportunity

Figure 8: Global Anti-α4β7 Integrin Monoclonal Antibody Market: Restraint

Figure 9: Global Anti-α4β7 Integrin Monoclonal Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Anti-α4β7 Integrin Monoclonal Antibody Market Value (USD Million) By Region

Figure 15: Global Anti-α4β7 Integrin Monoclonal Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Anti-α4β7 Integrin Monoclonal Antibody Market Value (USD Million) By Region

Figure 23: Global Anti-α4β7 Integrin Monoclonal Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global Anti-α4β7 Integrin Monoclonal Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Anti-α4β7 Integrin Monoclonal Antibody Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Anti-α4β7 Integrin Monoclonal Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Anti-α4β7 Integrin Monoclonal Antibody Market Value (USD Million) By Region

Table 10: Global Anti-α4β7 Integrin Monoclonal Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Anti-α4β7 Integrin Monoclonal Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Anti-α4β7 Integrin Monoclonal Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Anti-α4β7 Integrin Monoclonal Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Takeda Basic Information And Sales Area

Table 31: Takeda. Products Portfolio

Table 32: Biogen Basic Information And Sales Area

Table 33: Biogen. Products Portfolio

Table 34: Sandoz Basic Information And Sales Area

Table 35: Sandoz. Products Portfolio

Table 36: Novartis Basic Information And Sales Area

Table 37: Novartis. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Application

Table 39: Global Market Share (%) By Application (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Types

Table 41: Global Market Share (%) By Types (2032)

Table 42: Global Anti-α4β7 Integrin Monoclonal Antibody Market Value (USD Million) By Region

Table 43: Global Anti-α4β7 Integrin Monoclonal Antibody Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Application

Table 46: North America Market Value (USD Million) (2025-2032) By Types

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Application

Table 49: Europe Market Value (USD Million) (2025-2032) By Types

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Application

Table 55: South America Market Value (USD Million) (2025-2032) By Types

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

FAQs

1. What is the current Anti-α4β7 Integrin Monoclonal Antibody market size?

Global Anti-α4β7 Integrin Monoclonal Antibody market size surpassed USD 1.8 billion in 2023, driven by rising biologics adoption in inflammatory bowel disease and expanding reimbursed indications.

2. What is the future outlook and forecast CAGR?

Analysts project a robust 12% CAGR through 2030, lifting the future outlook to USD 3.7 billion, underpinned by label extensions, real-world evidence studies, and combination biologic regimens.

3. What are the key market drivers?

Key drivers include unmet needs in ulcerative colitis and Crohn’s disease, favorable payor coverage, rapid shift from steroids to targeted biologics, and accelerating early endoscopy diagnosis driving therapy initiation.

4. Which challenges restrain growth?

High treatment cost, stringent REMS requirements, biosimilar threats post-2028, and emerging JAK inhibitors intensify competitive pressure, limiting patient access in cost-sensitive healthcare systems.

5. Which region leads adoption?

North America commands 58% share, fueled by U.S. gastroenterology prescribing habits, comprehensive insurance, and ongoing pivotal trials. Europe follows, propelled by EMA label harmonization and country-specific tender uptake.

6. Who are the top companies?

Takeda (Entyvio originator) dominates; competitive landscape includes Celltrion, Sandoz, and Biocon gearing for biosimilars, alongside early-stage innovators like Morphic and Protagonist exploring oral integrin modulators.

7. What future opportunities exist?

Future outlook highlights pediatric Crohn’s approval, subcutaneous formulations enabling home administration, and strategic combinations with IL-23 blockers, potentially doubling eligible patient pools and extending lifecycle revenues.

8. How is technology impacting the market?

AI-driven patient stratification accelerates clinical recruitment, while continuous manufacturing cuts COGS by 30%, enhancing profitability and supporting Anti-α4β7 Integrin Monoclonal Antibody market size expansion amid pricing scrutiny.

9. What is the regulatory landscape?

FDA and EMA maintain expedited review pathways for gut-selective biologics; however, comparative effectiveness data against TNF-α inhibitors is now mandatory, shaping trial designs and label negotiations.

10. How will biosimilars reshape the market after 2028?

Biosimilar entry is projected to erode 35% of originator sales by 2032, triggering price resets but simultaneously expanding volume in emerging markets where Anti-α4β7 Integrin Monoclonal Antibody access remains sub-20%.

Contact for Full Report

Loading report content...

What Is the Global Anti-α4β7 Integrin Monoclonal Antibody Market Worth in 2026?

Market Snapshot

Anti-α4β7 Integrin Monoclonal Antibody Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Anti-α4β7 Integrin Monoclonal Antibody Segmentation

Anti-α4β7 Integrin Monoclonal Antibody Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Anti-α4β7 Integrin Monoclonal Antibody market size?

2. What is the future outlook and forecast CAGR?

3. What are the key market drivers?

4. Which challenges restrain growth?

5. Which region leads adoption?

6. Who are the top companies?

7. What future opportunities exist?

8. How is technology impacting the market?

9. What is the regulatory landscape?

10. How will biosimilars reshape the market after 2028?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Anti-α4β7 Integrin Monoclonal Antibody Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Anti-α4β7 Integrin Monoclonal Antibody Segmentation

Anti-α4β7 Integrin Monoclonal Antibody Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Anti-α4β7 Integrin Monoclonal Antibody market size?

2. What is the future outlook and forecast CAGR?

3. What are the key market drivers?

4. Which challenges restrain growth?

5. Which region leads adoption?

6. Who are the top companies?

7. What future opportunities exist?

8. How is technology impacting the market?

9. What is the regulatory landscape?

10. How will biosimilars reshape the market after 2028?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation